Results 31 to 40 of about 1,950 (155)

Changes of biomarkers for erythropoiesis, iron metabolism, and FGF23 by supplementation with roxadustat in patients on hemodialysis

Scientific Reports, 2023
This study aimed to confirm changes in biomarkers of erythropoiesis and iron metabolism and serum fibroblast growth factor 23 (FGF-23) during darbepoetin-α treatment and then switching to the hypoxia-inducible factor prolyl hydroxylase inhibitor ...
Shunsuke Yoshida, Tomohiro Saito, Keigo Shibagaki, Keiichi Hirao, Takatoshi Yuza, Naohisa Tomosugi, Hirokazu Honda   +6 more
doaj   +1 more source

Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis

Frontiers in Medicine, 2021
Background: Roxadustat, a hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI), has been used to treat anemia in patients with chronic kidney disease (CKD).
Chao Liu, Zhangning Fu, Jiawei Jiang, Kun Chi, Xiaodong Geng, Zhi Mao, Chengcheng Song, Guannan Sun, Quan Hong, Guangyan Cai, Xiangmei Chen, Xuefeng Sun   +11 more
doaj   +1 more source

Comparison between the influence of roxadustat and recombinant human erythropoietin treatment on blood pressure and cardio-cerebrovascular complications in patients undergoing peritoneal dialysis

Frontiers in Medicine, 2023
IntroductionRoxadustat treatment in PD patients is equivalent to ESAs in increasing hemoglobin (Hb). But blood pressure, cardiovascular parameters, cardio-cerebrovascular complications and prognosis in the two groups before and after treatment has not ...
Shuiqin Cheng, Tingting Zhou, Le Yu, Zhihong Zhang, Yunmin Chen, Man Zhang, Jingjing Cui, Wenxin Yu, Jian Zhou, Yusheng Yu   +9 more
doaj   +1 more source

Therapeutic Potential of the Prolyl Hydroxylase Inhibitor Roxadustat in a Mouse Hindlimb Lymphedema Model [PDF]

, 2023
Background: Lymphedema is an intractable disease with no curative treatment available. Conservative treatment is the mainstay, and new drug treatment options are strongly needed.
Masayuki Osawa, Emi Funayama, Yoshitada Hoshino, Taku Maeda, Masahiro Hojo, Hojo, Masahiro, Yamamoto, Yuhei, Hoshino, Yoshitada, Maeda, Taku, Yuhei Yamamoto, Takahiro Miura, Kosuke Ishikawa, Miura, Takahiro, Ishikawa, Kosuke, Osawa, Masayuki, Funayama, Emi   +15 more
core   +1 more source

HYDROLYTIC DEGRADATION STUDY OF ROXADUSTAT BY RP-HPLC AND HPTLC

, 2023
Objective: Simple, rapid RP-HPLC and HPTLC methods have been developed in order to study the degradation of Roxadustat under various stress conditions. The Kinetics of hydrolytic degradation is studied.
DAMLE, MRINALINI C., SONULE, JAY A.
core   +1 more source

A Scalable Synthesis of Roxadustat (FG-4592)

, 2021
A scalable five-step protocol for synthesis of roxadustat, an orally administered hypoxia-inducible factor-propyl hydroxylase inhibitor (HIF-PHI), was developed with an emphasis placed on aspects of medicinal chemistry.
Filip Šembera (2573536), Stanislav Rádl (11286511), Igor Čerňa (2186554), Ondřej Píša (11286508)   +3 more
core   +1 more source

A Pharmacodynamic Evaluation of the Protective Effects of Roxadustat Against Hypoxic Injury at High Altitude

, 2023
Qianwen Guo,1,2,* Xue Li,1,* Wenbin Li,1 Rong Wang,1 Anpeng Zhao,1 Zihan Wang1,2 1Pharmacy of the 940th Hospital of PLA Joint Logistics Support Force, Lanzhou, People’s Republic of China; 2School of Pharmacy, Gansu University of Traditional ...
Li W, Li X, Wang R, Zhao A, Guo Q, Wang Z   +5 more
core  

Co-Administration of Roxadustat and Zinc Stabilizes Both Serum Copper and Zinc Concentrations in Patients Undergoing Hemodialysis

, 2023
Patients undergoing hemodialysis often require zinc supplementation owing to hypozincemia, which may reduce serum copper concentrations. However, hypoxia-inducible factor–prolyl hydroxylase inhibitors (HIF-PHIs), which are used to treat renal anemia ...
Akira Takahashi
core   +1 more source

Red blood cell lifespan in long-term hemodialysis patients treated with roxadustat or recombinant human erythropoietin

Renal Failure, 2021
Introduction A significant decrease in red blood cell (RBC) survival has been observed in patients with renal failure, which is supposed to contribute to renal anemia. The aim of this observational study was to determine RBC survival in hemodialysis (HD)
Xiaowei Yang, Bing Zhao, Jing Wang, Lei Wang, Min Tao, Jing Lu, Jiangong Lin, Jing Sun, Rong Wang   +8 more
doaj   +1 more source

Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat

, 2021
The pharmacokinetics of roxadustat are well characterized, with an apparent volume of distribution after oral administration of 22-57 L, apparent clearance of 1.2-2.65 L/h, and renal clearance of 0.030-0.026 L/h in healthy volunteers; the elimination ...
Czock, David, Keller, Frieder
core   +1 more source